ClinicalTrials.gg
RecruitingNCT07201012SMT-SLUpdated Jun 22, 2026

Determining the Prevalence of Muir-Torre Syndrome in Patients With Lynch Syndrome

An interventional study of Sampling of suspected skin lesions (in accordance with good care practices). and Constitution of a biobank in Basal Cell Carcinoma of Skin, Site Unspecified, Epidermoid Carcinoma and Lynch Syndrome, sponsored by Centre Hospitalier Universitaire de Nīmes. Recruiting at 1 site in France. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by Centre Hospitalier Universitaire de Nīmes · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Carcinoma, Basal Cell with a site in France — 7 open to participants now, 8 under way, 1 of them phase 3. Carcinoma, Basal Cell · France.

Planned enrollment
8th of 23
150 · median 111
Started
2026
with 1 other
No phase
7 of 33
3 open now
Registered
32nd of 33
by date
Lead sponsor
1 of 33
Centre Hospitalier Universitaire de Nīmes

Among the 33 studies in Carcinoma, Basal Cell with a site in France, this one is the 8th largest by planned enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2026, is one of 7 with no phase, and was the 32nd registered.

Carcinoma, Basal Cell

389 studies on the registry are indexed under Carcinoma, Basal Cell; 69 are open to participants now.

Browse Carcinoma, Basal Cell studies →

Open to participants now

7 of the 33 studies in Carcinoma, Basal Cell with a site in France are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 53 Carcinoma, Basal Cell studies recruiting now, 49 (92%) set no upper age limit and none (0%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Carcinoma, Basal Cell with a site in France, or all of them as a file.
02

Study summary

The main aim of this study is to determine the prevalence of Muir-Torre syndrome (MTS) in the population of patients with Lynch syndrome (LS) confirmed by genetic analysis. Other aims include describing the dermatological clinical manifestations of these patients in order to describe any possible new cutaneous manifestations of this syndrome. Another aim is to use molecular biology (microsatellite instability) and immunohistochemistry to analyze non-sebaceous skin lesions and deep-seated tumors that do not belong to the narrow spectrum of Lynch syndrome, and determine whether their occurrence in these patients is related to the genetic syndrome. The follow-up of these tumors (screening for new tumors) in patients with SL, as recommended by the learned societies, will also be evaluated. Finally, a biobank of cutaneous and deep tumour lesions in paraffin (retrospective) and smears of cutaneous lesions and healthy tissue (prospective) will be set up.

Read the detailed description

Muir-Torre Syndrome (MTS) is an autosomal dominant disease described independently by Muir et al. in 1967 and Torre in 1968, defined by the association of a visceral tumor of the Lynch spectrum (colorectal, endometrial, urinary excretory tract, biliary tract, small intestine, stomach or glioblastoma carcinomas) and sebaceous skin tumors and/or multiple keratoacanthomas.

Histo-molecular examination of tumors for TMS/SL is based on 2 techniques, each focusing on a different aspect of TMS pathophysiology.

Immunohistochemistry (IHC) studies the presence of proteins from the MisMatch Repair (MMR) system in lesional tissues, and an absence of expression of one of these proteins is the physical translation of an abnormality in the MMR pathway, for which the presence of a constitutional mutation in one of the MMR system genes (MLH1, PMS2, MSH2, MSH6) is responsible. An IHC-deficient MMR phenotype (dMMR) results in a complete loss of expression of one or more MMR proteins in tumor cells, with expression maintained in "normal" cells (connective cells, immune cells, non-tumor epithelial cells).

Molecular biology or microsatellite instability (MSI) testing focuses on the molecular repercussions of MMR pathway failure. The aim of this technique is to determine the presence of microsatellite marker instability in tumor tissue. While for colorectal tumors, a comparative analysis of the patient's healthy tissue can be dispensed with, for other organs on the Lynch spectrum, including sebaceous tumors, a comparison with DNA from normal tissue can help interpret the results.

The incidence of TMS among patients with genetically proven SL is poorly known. Two studies have shown a prevalence of 9.2%, both involving American patients (1,2). These were 2 retrospective chart-based studies, the skin tumors not having been re-read for diagnostic confirmation.

These patients may also develop skin tumors not belonging to the SMT-SL spectrum, such as basal cell carcinomas (BCCs), squamous cell carcinomas (SCCs) or melanocytic tumors (melanomas and nevi). These skin and deep tumors (visceral tumors) not belonging to the Lynch spectrum of patients with proven SL have rarely been systematically studied for a dMMR phenotype.

French societies (INCa, Société Française de Gastroentérologie) have proposed the management of any patient with a mutation in one of the MMR system genes. Compliance with follow-up is a major public health issue. Digestive follow-up (regular colonoscopies) is only 68%, whereas gynecological follow-up is only 73% to 80%. Other types of follow-up, notably dermatological, have rarely been analyzed, and above all we have no data on compliance in France.

03

Conditions studied

  • Basal Cell Carcinoma of Skin, Site Unspecified
  • Epidermoid Carcinoma
  • Lynch Syndrome
  • Muir-Torre Syndrome

Keywords

  • Carcinoma
  • Screening
  • Skin cancer
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with a germline alteration of one of the MMR (MisMatch Repair) pathway genes (MLH1, PMS2, MSH2, MSH6) proven by constitutional genetic analysis (genetically authenticated Lynch syndrome).
  • Patient followed at Nîmes University Hospital.
  • Patient having given free and .
  • Person affiliated to or benefiting from a social security scheme.

Exclusion criteria

Exclusion Criteria:

  • Person under court protection, guardianship or curatorship.
  • A person who is unable to give consent.
  • Person for whom it is impossible to give informed information.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Other
    Patients with Lynch syndrome undergoing screening for Muir-Torre syndrome

    Diagnostic Test: Sampling of suspected skin lesions (in accordance with good care practices). · Genetic: Constitution of a biobank

Interventions

  • Diagnostic testSampling of suspected skin lesions (in accordance with good care practices).

    Sampling of suspected skin lesions (in accordance with good care practices) and swabbing of skin microbiota.

  • GeneticConstitution of a biobank

    Collection of previously excised cutaneous and deep tumour lesions kept in a public or private pathological anatomy facility for these patients

06

What researchers measure

Primary outcomes

  1. Prevalence of Muir-Torre syndrome (MTS) in the population of patients with Lynch syndrome

    Proportion of patients with Muir-Torre Syndrome confirmed by the occurrence of a sebaceous tumor (sebaceous adenoma, sebaceoma, sebaceous carcinoma) or several keratoacanthomas among patients with Lynch Syndrome. These tumors may or may not have had the mismatch repair system analyzed by immunohistochemistry (analysis of the 4 antibodies MLH1, PMS2, MSH2, MSH6) or by molecular biology (search for microsatellite instability). If the mismatch repair system has been studied, it must be deficient and the proteins absent on immunohistochemistry must be consistent with the mutated gene in Lynch Syndrome. If a block or slides are still available, sebaceous skin tumors or keratoacanthomas will be re-evaluated at Nîmes University Hospital for confirmation of the diagnosis.

    Time frame: Up to 6 months after inclusion

Secondary outcomes

  1. Dermatological clinical manifestations in patients with confirmed Lynch Syndrome

    Presence of clinical dermatological signs associated with Lynch syndrome. YES/NO

    Time frame: Up to 6 months after inclusion

  2. Non-sebaceous skin lesions and Deep-seated tumors not belonging to the narrow spectrum of Lynch syndrome. Presence of antibody MLH1

    Molecular analysis (MSI test) and immunohistochemical analysis. Presence of antibody MLH1 on other tumour tissues (YES/NO) to determine the mismatch repair deficient (or MSI = pathological) or proficient (or MSS = normal) status of these lesions (and thereby their link with Muir-Torre syndrome).

    Time frame: Up to 6 months after inclusion

  3. Non-sebaceous skin lesions and Deep-seated tumors not belonging to the narrow spectrum of Lynch syndrome. Presence of antibody PMS2

    Molecular analysis (MSI test) and immunohistochemical analysis. Presence of antibody PMS2 on other tumour tissues (YES/NO) to determine the mismatch repair deficient (or MSI = pathological) or proficient (or MSS = normal) status of these lesions (and thereby their link with Muir-Torre syndrome).

    Time frame: Up to 6 months after inclusion

  4. Non-sebaceous skin lesions and Deep-seated tumors not belonging to the narrow spectrum of Lynch syndrome. Presence of antibody MSH2

    Molecular analysis (MSI test) and immunohistochemical analysis. Presence of antibody MSH2 on other tumour tissues (YES/NO) to determine the mismatch repair deficient (or MSI = pathological) or proficient (or MSS = normal) status of these lesions (and thereby their link with Muir-Torre syndrome).

    Time frame: Up to 6 months after inclusion

  5. Non-sebaceous skin lesions and Deep-seated tumors not belonging to the narrow spectrum of Lynch syndrome. Presence of antibody MSH6

    Molecular analysis (MSI test) and immunohistochemical analysis. Presence of antibody MSH6 (YES/NO) on other tumour tissues, to determine the mismatch repair deficient (or MSI = pathological) or proficient (or MSS = normal) status of these lesions (and thereby their link with Muir-Torre syndrome).

    Time frame: Up to 6 months after inclusion

Other outcomes

  1. Constitution of a biobank

    Collection of previously excised cutaneous and deep tumour lesions kept in a public or private pathological anatomy facility for these patients

    Time frame: Up to 6 months after inclusion

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Zhong CS, Horiguchi M, Uno H, Ukaegbu C, Chittenden A, LeBoeuf NR, Syngal S, Nambudiri VE, Yurgelun MB. Clinical factors associated with skin neoplasms in individuals with Lynch syndrome in a longitudinal observational cohort. J Am Acad Dermatol. 2023 Jun;88(6):1282-1290. doi: 10.1016/j.jaad.2023.01.035. Epub 2023 Feb 9. PubMed 36773823 ↗
  • South CD, Hampel H, Comeras I, Westman JA, Frankel WL, de la Chapelle A. The frequency of Muir-Torre syndrome among Lynch syndrome families. J Natl Cancer Inst. 2008 Feb 20;100(4):277-81. doi: 10.1093/jnci/djm291. Epub 2008 Feb 12. PubMed 18270343 ↗
  • Adan F, Crijns MB, Zandstra WSE, Bekkenk MW, Bleeker FE, Dekker E, van Leerdam ME. Cumulative risk of skin tumours in patients with Lynch syndrome. Br J Dermatol. 2018 Aug;179(2):522-523. doi: 10.1111/bjd.16552. Epub 2018 May 29. No abstract available. PubMed 29542113 ↗
  • Aziz S, O'Sullivan H, Heelan K, Alam A, McVeigh TP. Characterization of sebaceous and non-sebaceous cutaneous manifestations in patients with lynch syndrome: a systematic review. Fam Cancer. 2023 Apr;22(2):167-175. doi: 10.1007/s10689-022-00319-8. Epub 2022 Nov 23. PubMed 36418753 ↗
  • Latham A, Srinivasan P, Kemel Y, Shia J, Bandlamudi C, Mandelker D, Middha S, Hechtman J, Zehir A, Dubard-Gault M, Tran C, Stewart C, Sheehan M, Penson A, DeLair D, Yaeger R, Vijai J, Mukherjee S, Galle J, Dickson MA, Janjigian Y, O'Reilly EM, Segal N, Saltz LB, Reidy-Lagunes D, Varghese AM, Bajorin D, Carlo MI, Cadoo K, Walsh MF, Weiser M, Aguilar JG, Klimstra DS, Diaz LA Jr, Baselga J, Zhang L, Ladanyi M, Hyman DM, Solit DB, Robson ME, Taylor BS, Offit K, Berger MF, Stadler ZK. Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. J Clin Oncol. 2019 Feb 1;37(4):286-295. doi: 10.1200/JCO.18.00283. Epub 2018 Oct 30. PubMed 30376427 ↗
  • Poumeaud F, Valentin T, Vande Perre P, Jaffrelot M, Bonnet D, Chibon F, Chevreau C, Selves J, Guimbaud R, Fares N. Special features of sarcomas developed in patients with Lynch syndrome: A systematic review. Crit Rev Oncol Hematol. 2023 Aug;188:104055. doi: 10.1016/j.critrevonc.2023.104055. Epub 2023 Jun 8. PubMed 37301271 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Nov 2026, 8 months after the start.

Of 50 interventional studies with no phase under Carcinoma, Basal Cell, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 64. This study's planned 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2025
First posted
Oct 1, 2025
StartActual
Mar 13, 2026
Primary completionEst.
Nov 2026
CompletionEst.
Dec 2027
Last update
Jun 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07201012
Responsible party
Sponsor
First posted
Oct 1, 2025
Start date
Mar 13, 2026
Primary completion
Nov 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jun 22, 2026

Study contacts

Eric FROUIN, Dr.
Contact
Eric.frouin@chu-nimes.fr
+334 66 68 82 74
Anissa MEZGARI
Contact
drc@chu-nimes.fr
+44466684236
Pierre STOEBNER, Prof.
principal investigator · Nîmes University Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion